Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Net Margin (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Net Margin for 14 consecutive years, with 0.41% as the latest value for Q2 2025.

  • On a quarterly basis, Net Margin rose 890.0% to 0.41% in Q2 2025 year-over-year; TTM through Dec 2025 was 0.19%, a 223.0% increase, with the full-year FY2025 number at 0.93%, up 603.0% from a year prior.
  • Net Margin was 0.41% for Q2 2025 at Aytu Biopharma, up from 0.29% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 2.3% in Q3 2024 to a low of 219.28% in Q1 2022.
  • A 5-year average of 36.42% and a median of 8.4% in 2023 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: plummeted -9534bps in 2021, then soared 18761bps in 2023.
  • Aytu Biopharma's Net Margin stood at 49.94% in 2021, then soared by 49bps to 25.47% in 2022, then soared by 82bps to 4.48% in 2023, then surged by 117bps to 0.76% in 2024, then tumbled by -46bps to 0.41% in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Net Margin are 0.41% (Q2 2025), 0.29% (Q1 2025), and 0.76% (Q4 2024).